Voiding Dysfunctions in Patients with Non‐Hunner’s Ulcer Interstitial Cystitis/ Bladder Pain Syndrome Do Not Affect Long‐term Treatment Outcome

2021 ◽  
Author(s):  
Wan‐Ru Yu ◽  
Wei‐Chuan Chang ◽  
Hann‐Chorng Kuo
Keyword(s):  
Treatment Outcome ◽  
Interstitial Cystitis ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Term Treatment ◽  
Bladder Pain ◽  
Long Term Treatment ◽  
Voiding Dysfunctions

scholarly journals The voiding dysfunctions in patients with non-Hunner-type interstitial cystitis/bladder pain syndrome do not affect long-term treatment outcome

2021 ◽  
Author(s):  
Wan-Ru Yu ◽  
Wei-Chuan Chang ◽  
Hann-Chorng Kuo
Keyword(s):  
Treatment Outcome ◽  
Interstitial Cystitis ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Term Treatment ◽  
Bladder Pain ◽  
Long Term Treatment ◽  
Significant Difference ◽  
Voiding Dysfunctions

Aims: The role of urodynamic studies in the diagnosis and prognosis of interstitial cystitis/bladder pain syndrome (IC/BPS) remains controversial. We evaluated the correlation of baseline voiding dysfunctions with long-term treatment outcome in a large cohort of patients with IC/BPS. Methods: We studied 211 patients with nonulcerative IC/BPS. All patients underwent video urodynamic examination at baseline to identify their voiding conditions and they received subsequent treatments. The primary endpoint was the global response assessment (GRA) at the current interview. Secondary endpoints included O’Leary-Sant score (OSS), Visual Analog Scale (VAS) for pain, and the rate of IC symptom flare-up. Results: Mean patient age was 56.8 ± 12.8 years and mean IC symptom duration was 16.0 ± 9.9 years. At baseline, 83 (39.3%) patients had a voiding problem and 62.7% had one to three comorbidities. The duration, comorbidity, treatments, changes in OSS and VAS, maximum bladder capacity (MBC), glomerulations, GRA, and flare-up rate were not significantly different among the different voiding subtypes. When we divided the patients by their voiding conditions of normal (n = 32) and hypersensitive bladder with (n = 76) and without (n = 103) voiding dysfunctions, only MBC (P = 0.002) and glomerulation (P = 0.021) demonstrated a significant difference. When we analyzed subgroups by GRA, patients with a GRA ≥ 2 had a significantly shorter disease duration. There also were significant associations between GRA and the changes in OSS and VAS (P < 0.001). Conclusions: Voiding dysfunctions in patients with non-Hunner IC/BPS do not affect long-term treatment outcome.

Long-term outcomes of intravesical dimethyl sulfoxide/heparin/hydrocortisone therapy for interstitial cystitis/bladder pain syndrome

2016 ◽  
Vol 28 (7) ◽  
pp. 1085-1089 ◽  
Author(s):  
Yik N. Lim ◽  
Peter Dwyer ◽  
Christine Murray ◽  
Debjyoti Karmakar ◽  
Anna Rosamilia ◽  
...  
Keyword(s):  
Dimethyl Sulfoxide ◽  
Interstitial Cystitis ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Long Term Outcomes ◽  
Bladder Pain

Long-Term Results of Reconstructive Surgery in Patients with Bladder Pain Syndrome/Interstitial Cystitis: Subtyping Is Imperative

Urology ◽  
2007 ◽  
Vol 70 (4) ◽  
pp. 638-642 ◽  
Author(s):  
Josefine Rössberger ◽  
Magnus Fall ◽  
Olof Jonsson ◽  
Ralph Peeker
Keyword(s):  
Interstitial Cystitis ◽  
Reconstructive Surgery ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Long Term Results ◽  
Bladder Pain

642 INTRA-TRIGONAL INJECTION OF BOTULINUM TOXIN A IN PATIENTS WITH REFRACTORY BLADDER PAIN SYNDROME/INTERSTITIAL CYSTITIS: LONG TERM RESULTS

2010 ◽  
Vol 9 (2) ◽  
pp. 213
Author(s):  
R.M.C.A. Pinto ◽  
T.A. Lopes ◽  
A.S. Silva ◽  
Silva J.F. Alturas ◽  
C.P. Martins Da Silva ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Interstitial Cystitis ◽  
Botulinum Toxin A ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Long Term Results ◽  
Toxin A ◽  
Bladder Pain
Sign in / Sign up

Export Citation Format

Share Document